Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by Dibah42on Jul 01, 2020 7:05am
200 Views
Post# 31211512

Some thoughts on the news

Some thoughts on the news1)  PBI 4050 for anti fibrotic activity.  Launching Phase 1 MAD.

Question is why?  And why now?  They have abundant data on hand from multiple previous (Phase 1 & 2)   trials establishing SAFETY of  PBI 4050 and its cognate PBI 1402 at varying dosages of 8, 12, 16 mg  etc.  PL once told me that he ascribed his own good health to a daily dose despite his stressful life living out of a suitcase in airports and hotel rooms.
The question that remained unanswered was always one of EFFICACY  in mitigating fibrosis in sundry visceral organs.  Of course many claims were made SUGGESTING efficacy using proof of concept studies, in vitro and animal models over the two decades  that I have followed this company but NEVER once proven using a randomized placebo controlled Phase 3 trial.  EVER!
Are they now, in order to achieve some aspirational end-point of efficacy, pushing the boundaries of dosage?  

2)  Commencing plasma collection from recovering Covid 19 patients.
The company holds most of the critical patents in PPPP and yet the way the announcement reads it appears that purification is being relegated to third parties.  So what's the business model?  Where's the monetization?  Is LMNL now merely a collection agency?  
<< Previous
Bullboard Posts
Next >>